370 related articles for article (PubMed ID: 1581909)
21. Association of E-cadherin and beta-catenin with metastasis in nasopharyngeal carcinoma.
Li Z; Ren Y; Lin SX; Liang YJ; Liang HZ
Chin Med J (Engl); 2004 Aug; 117(8):1232-9. PubMed ID: 15361301
[TBL] [Abstract][Full Text] [Related]
22. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
[TBL] [Abstract][Full Text] [Related]
23. Dominant role of E-cadherin in the progression of bladder cancer.
Imao T; Koshida K; Endo Y; Uchibayashi T; Sasaki T; Namiki M
J Urol; 1999 Feb; 161(2):692-8. PubMed ID: 9915485
[TBL] [Abstract][Full Text] [Related]
24. [Function of IL-18 in promoting metastasis of lung cancer].
Jiang DF; Liu WL; Lu YL; Qiu ZY; He FC
Zhonghua Zhong Liu Za Zhi; 2003 Jul; 25(4):348-52. PubMed ID: 12921563
[TBL] [Abstract][Full Text] [Related]
25. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
Chung LW; Baseman A; Assikis V; Zhau HE
J Urol; 2005 Jan; 173(1):10-20. PubMed ID: 15592017
[TBL] [Abstract][Full Text] [Related]
26. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
[TBL] [Abstract][Full Text] [Related]
27. Human prostate cancer progression models and therapeutic intervention.
Chung LW; Kao C; Sikes RA; Zhau HE
Hinyokika Kiyo; 1997 Nov; 43(11):815-20. PubMed ID: 9436028
[TBL] [Abstract][Full Text] [Related]
28. The Src-suppressed C kinase substrate, SSeCKS, is a potential metastasis inhibitor in prostate cancer.
Xia W; Unger P; Miller L; Nelson J; Gelman IH
Cancer Res; 2001 Jul; 61(14):5644-51. PubMed ID: 11454719
[TBL] [Abstract][Full Text] [Related]
29. Expression of peroxisome proliferator-activated receptor gamma, E-cadherin and matrix metalloproteinases-2 in gastric carcinoma and lymph node metastases.
He Q; Chen J; Lin HL; Hu PJ; Chen MH
Chin Med J (Engl); 2007 Sep; 120(17):1498-504. PubMed ID: 17908458
[TBL] [Abstract][Full Text] [Related]
30. Genetic factors and suppression of metastatic ability of prostatic cancer.
Ichikawa T; Ichikawa Y; Isaacs JT
Cancer Res; 1991 Jul; 51(14):3788-92. PubMed ID: 2065333
[TBL] [Abstract][Full Text] [Related]
31. Role of notch-1 and E-cadherin in the differential response to calcium in culturing normal versus malignant prostate cells.
Dalrymple S; Antony L; Xu Y; Uzgare AR; Arnold JT; Savaugeot J; Sokoll LJ; De Marzo AM; Isaacs JT
Cancer Res; 2005 Oct; 65(20):9269-79. PubMed ID: 16230388
[TBL] [Abstract][Full Text] [Related]
32. CL1-GFP: an androgen independent metastatic tumor model for prostate cancer.
Patel BJ; Pantuck AJ; Zisman A; Tsui KH; Paik SH; Caliliw R; Sheriff S; Wu L; deKernion JB; Tso CL; Belldegrun AS
J Urol; 2000 Oct; 164(4):1420-5. PubMed ID: 10992426
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of E-cadherin and beta-catenin proteins in metastatic prostate cancer cells in bone.
Saha B; Arase A; Imam SS; Tsao-Wei D; Naritoku WY; Groshen S; Jones LW; Imam SA
Prostate; 2008 Jan; 68(1):78-84. PubMed ID: 18008331
[TBL] [Abstract][Full Text] [Related]
34. Expression of E-cadherin and nm23 is associated with the clinicopathological factors of human non-small cell lung cancer in China.
Chen XF; Zhang HT; Qi QY; Sun MM; Tao LY
Lung Cancer; 2005 Apr; 48(1):69-76. PubMed ID: 15777972
[TBL] [Abstract][Full Text] [Related]
35. Cell-cell adhesion molecules and signaling intermediates and their role in the invasive potential of prostate cancer cells.
Davies G; Jiang WG; Mason MD
J Urol; 2000 Mar; 163(3):985-92. PubMed ID: 10688036
[TBL] [Abstract][Full Text] [Related]
36. Altered localization of E-cadherin and alpha-catenin in rat esophageal tumors.
Khare L; Sabourin CL; De Young BR; Jamasbi RJ; Stoner GD
Int J Oncol; 1999 Jan; 14(1):33-40. PubMed ID: 9863006
[TBL] [Abstract][Full Text] [Related]
37. Relationship between tumor size and curability of prostatic cancer by combined chemo-hormonal therapy in rats.
Isaacs JT
Cancer Res; 1989 Nov; 49(22):6290-4. PubMed ID: 2804976
[TBL] [Abstract][Full Text] [Related]
38. Automated quantitative analysis of E-cadherin expression in lymph node metastases is predictive of survival in invasive ductal breast cancer.
Harigopal M; Berger AJ; Camp RL; Rimm DL; Kluger HM
Clin Cancer Res; 2005 Jun; 11(11):4083-9. PubMed ID: 15930343
[TBL] [Abstract][Full Text] [Related]
39. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer.
Umbas R; Isaacs WB; Bringuier PP; Schaafsma HE; Karthaus HF; Oosterhof GO; Debruyne FM; Schalken JA
Cancer Res; 1994 Jul; 54(14):3929-33. PubMed ID: 7518346
[TBL] [Abstract][Full Text] [Related]
40. Expression and role of Foxa proteins in prostate cancer.
Mirosevich J; Gao N; Gupta A; Shappell SB; Jove R; Matusik RJ
Prostate; 2006 Jul; 66(10):1013-28. PubMed ID: 16001449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
